Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DELFLEX is a sterile, non-pyrogenic peritoneal dialysis solution containing dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, and magnesium chloride. Developed and manufactured by Fresenius Medical Care North America, it is indicated for the treatment of chronic kidney failure in patients undergoing peritoneal dialysis. The solution functions as both an osmotic agent and an electrolyte replenisher. Dextrose serves as the primary osmotic agent, creating a gradient across the peritoneal membrane to facilitate ultrafiltration (the removal of excess water). The electrolytes (sodium, calcium, magnesium, and chloride) and the lactate buffer work to correct systemic electrolyte imbalances and metabolic acidosis. DELFLEX is administered intraperitoneally and is available in various dextrose concentrations (e.g., 2.5%, 4.25%) to allow for individualized patient management based on their fluid and electrolyte needs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextrose monohydrate + sodium lactate + sodium chloride + calcium chloride + magnesium chloride.